Breaking News
1 hour ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
FDA grants Zydus priority review for saroglitazar NDA in PBC, setting a November 27, 2026 PDUFA date on Phase 3 EPICS-III data.
Pharma Now Editorial Team

Samsung Bioepis launches OPUVIZ, its aflibercept biosimilar referencing Eylea, as its fifth directly commercialized biosimilar across European markets.
Pharma Now Editorial Team

Sanofi's AccelRare receives Class A medical device classification in India, setting a regulatory reference point for AI pre-diagnostic tools in emerging markets.
Pharma Now Editorial Team

AstraZeneca secured 11 CDSCO approvals in FY26 as India revenue rose 33% YoY to Rs. 22.76 billion, with oncology contributing Rs. 16.1 billion.
Pharma Now Editorial Team
